Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Atherosclerosis Compendium

Genetics of Coronary Artery Disease

Ruth McPherson, Anne Tybjaerg-Hansen
Download PDF
https://doi.org/10.1161/CIRCRESAHA.115.306566
Circulation Research. 2016;118:564-578
Originally published February 18, 2016
Ruth McPherson
From the Department of Medicine, Atherogenomics Laboratory, Division of Cardiology, Ruddy Canadian Cardiovascular Genetics Center, University of Ottawa Heart Institute, Ottawa, Ontario, Canada (R.M.); and Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (A.T.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Tybjaerg-Hansen
From the Department of Medicine, Atherogenomics Laboratory, Division of Cardiology, Ruddy Canadian Cardiovascular Genetics Center, University of Ottawa Heart Institute, Ottawa, Ontario, Canada (R.M.); and Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (A.T.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Introduction
    • Genome-Wide Association Studies
    • Studies in Non-European Populations
    • Mendelian Randomization
    • Utility of a Genetic Risk Score for Risk Assessment and Treatment Decisions
    • Interrogation of Rare Coding Variants Contributing to CAD
    • Beyond the Single SNP
    • Systems Genetics Approach to Understanding the Genetic Basis of CAD
    • From Locus to Function
    • Summary
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Genetic factors contribute importantly to the risk of coronary artery disease (CAD), and in the past decade, there has been major progress in this area. The tools applied include genome-wide association studies encompassing >200 000 individuals complemented by bioinformatic approaches, including 1000 Genomes imputation, expression quantitative trait locus analyses, and interrogation of Encyclopedia of DNA Elements, Roadmap, and other data sets. close to 60 common SNPs (minor allele frequency>0.05) associated with CAD risk and reaching genome-wide significance (P<5×10−8) have been identified. Furthermore, a total of 202 independent signals in 109 loci have achieved a false discovery rate (q<0.05) and together explain 28% of the estimated heritability of CAD. These data have been used successfully to create genetic risk scores that can improve risk prediction beyond conventional risk factors and identify those individuals who will benefit most from statin therapy. Such information also has important applications in clinical medicine and drug discovery by using a Mendelian randomization approach to interrogate the causal nature of many factors found to associate with CAD risk in epidemiological studies. In contrast to genome-wide association studies, whole-exome sequencing has provided valuable information directly relevant to genes with known roles in plasma lipoprotein metabolism but has, thus far, failed to identify other rare coding variants linked to CAD. Overall, recent studies have led to a broader understanding of the genetic architecture of CAD and demonstrate that it largely derives from the cumulative effect of multiple common risk alleles individually of small effect size rather than rare variants with large effects on CAD risk. Despite this success, there has been limited progress in understanding the function of the novel loci; the majority of which are in noncoding regions of the genome.

  • coronary artery disease
  • genetics
  • genome-wide association study
  • Mendelian randomization analysis
  • polymorphism, single nucleotide

Introduction

Coronary artery disease (CAD) has important genetic underpinnings considered equivalent to that of environmental factors. The heritability of CAD has been estimated between 40% and 60%, on the basis of family and twin studies, a method that yields high precision despite potential bias (Vinkhuyzen et al1). In the Framingham Offspring Study, the age-specific incidence of CAD increased by >2-fold after adjustment for conventional CAD risk factors in participants with a family history of premature disease.2 The Swedish Twin registry reported on close to 21 000 subjects followed up for >35 years and calculated the heritability of fatal CAD events to be 0.57 and 0.38, for men and women, respectively. Of note, heritable effects are most manifest in younger individuals.3 This accords with other data, indicating that the genetic influence is the greatest for early-onset CAD events.4

Unraveling the genetic basis of CAD has evolved slowly during the past half-century. Candidate genes coding for proteins of known biological significance in a disease process seemed to provide a logical first step in understanding the genetics of common disease states. Populations of affected and unaffected individuals could be studied by genotyping common single-nucleotide polymorphisms (SNPs) within a gene and its regulatory sequences. Although economically attractive, this approach had many limitations. By definition, studies are limited to genes with a known or suspected role in defining a given phenotype and do not provide new insight into biological pathways leading to disease. Furthermore, candidate gene associations generally failed to replicate for multiple reasons, including statistical power related to inadequate, sample size, heterogeneity of causality, and population stratification.5 With the exception of rare monogenic disorders of lipid metabolism, such as familial hypercholesterolemia, there is as yet little support for a role of single-gene disorders in coronary atherosclerosis or plaque rupture as discussed below.

Genome-Wide Association Studies

Recent progress in understanding the genetics of CAD and other complex diseases has been driven by technological advances, including high-throughput DNA microarray technology using chips containing up to a million DNA markers consisting of single-nucleotide polymorphisms (SNPs). In the commercial arrays used for genome-wide association studies (GWASs), SNPs (generally 0.5–1 mol/L) are used to tag common variation (SNPs present in ≥5% of the population) across the human genome. Importantly, these are tag SNPs that point to a causative locus but are rarely functional variants. This approach makes use of linkage disequilibrium (LD) that is the nonrandom coinheritance of genetic variants across the human genome. Comparison of the allele frequency of each SNP in cases and controls as part of a GWAS provides an agnostic approach that involves no underlying assumption on candidate genes or pathways. However, the statistical bar for association is high; comparison of a million markers implies a P value of ≤5×10−8 for GWAS significance. Thus, success has been contingent on the allele frequency and effect size of a given variant and the recruitment of thousands of carefully phenotyped individuals with or without clinical evidence of CAD and collaboration among many groups across the world.

The first robust association with CAD identified by the GWAS approach, a 53-kb LD block containing multiple highly correlated SNPs at 9p21.3 locus, was identified by 3 independent groups in 2007.6–8 The early discovery of this risk locus was facilitated by its large effect size (>1.3) and risk allele frequency (≈0.48). Approximately 25% of Europeans carry 2 copies of the risk allele and have a 40% increased risk of CAD in general and a 2-fold risk of premature CAD. Here, it is notable that in the Ottawa Heart Study,6 an extreme phenotype approach was used comparing young patients with multivessel CAD to elderly, physically active, asymptomatic subjects. Although the discovery population consisted of only 322 cases and 311 controls, the lead SNP rs10757274 achieved a P value of 3.7×10−6. Consistently, in the large Coronary Artery Disease Genome-wide Replication and Meta-Analysis (CARDIoGRAM) study, the allele-specific odds ratio (OR) for CAD in subjects with onset before 50 years of age was 1.41 (confidence interval, 1.34–1.48) versus 1.24 (confidence interval, 1.20–1.28)4 for older individuals.4 The 9p21 locus is also associated with the extent and severity of atherosclerosis9,10 and with a higher risk allele frequency in subjects with multivessel disease.9 It has been consistently shown that the risk conferred by this locus is independent of known risk factors, including plasma lipids, blood pressure, diabetes mellitus, obesity, markers of inflammation, age, and sex. Several other vascular phenotypes are associated with the 9p21 risk alleles, including carotid atherosclerosis,11 stroke,12,13 peripheral arterial disease,14 and abdominal aortic aneurysm15 consistent with an effect on atherosclerosis. However, there is an important association with intracranial aneurysms,16 thus highlighting the possible effects on vascular wall integrity. Distinct haplotype blocks are associated with platelet reactivity17 and myocardial infarction versus atherosclerosis.18 There is also a surprising association with periodontitis.19,20

Since the 9p21 discovery in 2007, large meta-analyses of additional GWASs, the majority of which have been conducted in individuals of European descent, have identified additional loci of smaller effect size but with genome-wide (P<5×10−8) significance. This success has been built on large collaborative efforts, including the Myocardial Infarction Genomics Consortium,21 the CARDIoGRAM consortium,4 the Coronary Artery Disease (C4D) Genetics Consortium,22 CARDIoGRAMplusC4D,23 and others. The risk loci identified include genes known to function in lipoprotein metabolism, hypertension, and other CAD-associated phenotypes but, importantly, include several novel regions harboring genes of unknown relevance to atherosclerosis and plaque rupture, thus highlighting the discovery potential of the GWAS approach. Several risk regions exhibit pleiotropic effects; for example, ABO and SH2B3 associate with multiple CAD and non–CAD-related phenotypes. With the exception of the LPA gene24 encoding lipoprotein(a) and the 9p21.3 locus, the allele-specific ORs for CAD of replicated loci are <1.15, as might be expected for common variants affecting a complex trait.

GWASs of CAD have been designed to test the common disease–common variant hypothesis, and most have applied imputation from HapMap training sets interrogating mainly SNPs present in >5% of the population (minor allele frequency [MAF]>0.05). In contrast to HapMap, the 1000 Genomes Project phase 1, version 3 data set includes >38 million variants; half of which are present in <1 in 200 individuals (MAF<0.005), as well as insertions and deletions (indels). These data were leveraged in a recent meta-analysis led by Martin Farrall that included >185 000 individuals (60 801 CAD cases and 123 504 controls) from 48 studies providing imputed data on 9.4 million SNPs, including 2.7 million low-frequency SNPs (MAF, 0.005–0.05). The summary Manhattan plot is shown in Figure 1. By using both a recessive and an additive model of inheritance, 2 novel loci were identified that would have been missed by conventional analysis. In total, this analysis identified 10 novel CAD loci at GWAS significance, bringing the total number of replicated loci in European populations to 58 (Table 1). Here, it is notable that <25% of the significant loci are related to known CAD risk factors, highlighting the discovery potential of the GWAS approach. Joint association analysis using genome-wide complex trait analysis software revealed no evidence that the signal conferred by common SNPs was because of synthetic associations, that is, linkage with a rare variant(s) of high effect size.25

View this table:
  • View inline
  • View popup
Table 1.

Replicated Genome-Wide Significant Loci for CAD

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Manhattan plot of genome-wide association study (GWAS) meta-analysis that included ≈185 000 coronary artery disease (CAD) cases and controls from 48 studies providing 1000 Genomes–imputed data on 9.4 million single-nucleotide polymorphisms (SNPs), including 2.7 million low-frequency SNPs (minor allele frequency, 0.005–0.05). Two novel loci were identified that would have been missed by conventional analysis. The meta-analysis statistics have been adjusted for overdispersion (genomic control parameter, 1.18) and have been capped to P=1×10−20. The genome-wide significance threshold is shown as a horizontal blue line at P<5×10−8. Novel CAD loci are presented with red stacks and gene names. Previously reported loci showing GWAS significance are shown in brown, and those showing nominal significance (P<0.05) in this meta-analysis are shown in blue. Reprinted from Nikpay et al25 with permission of the publisher. Copyright ©2015, Nature Publishing Group.

The 48 GWAS significant loci previously identified explained only ≈11% of the estimated heritability of CAD. Here, beyond considering only GWAS significant loci (P≤5×10−8), an approximate joint association analysis was performed using genome-wide complex trait analysis software26,27 to identify 202 false discovery rate variants (q<0.05) in 129 loci. Thus, several loci contained multiple independent signals for CAD association. Together, the 202 independent variants explained ≈28% of predicted CAD heritability.25 Of these, 15 were of low frequency (MAF<0.05) and explained only ≈2% of CAD heritability. Here, it is important to acknowledge that GWAS analysis based on SNP array data has limited power to resolve genes with rare mutation burdens.25 Overall, this analysis not only provided new information on the genetic architecture of CAD but also strongly supports the conclusion that genetic susceptibility to CAD is largely derived from the effect of multiple common SNPs of small effect size. The 202 independent variants reaching a false discovery rate of q<0.05 showed independent enrichment across 11 cell types for histone/chromatin modifications, DNase I hypersensitive sites consistent with other data that GWAS signals are enriched in regulatory regions of the genome.28,29

Studies in Non-European Populations

The majority of GWASs for CAD have been carried out in populations of European white ancestry with smaller but important studies in East Asian, South Asian, and black populations. Haplotype blocks are segments of DNA that are known and shared within ancestral groups. Because of the recent arrival of humans into Europe, individuals of European ancestry are more similar to each other and have more correlated SNPs and longer haplotype blocks when compared with the more ancient and genetically diverse populations of African ancestry.30–32 The average haplotype block is ≈20.7 kb in European whites, ≈8.8 kb in blacks, and ≈ 25.2 kb in Han Chinese. Thus, fewer tag SNPs are required for genotyping a population of European or East Asian versus African ancestry. With the supposition that causal variants are shared among different populations, transethnic mapping by taking advantage of differences in LD and allele frequency might be expected to facilitate identification of causal variants. Here, the significantly shorter haplotype blocks in black populations could help to both fine-map association signals identified in European populations and identify novel ethnic-specific signals.33

Most of the disease-related GWAS loci discovered in Europeans have been replicated in populations of East Asian ancestry. A strong and significant correlation of ORs of specific SNPs for CAD and 27 other diseases across European and East Asian samples has recently been demonstrated, indicating that causal variants, in general, are shared between these 2 populations.34 As would be expected, the SNPs that failed replication in East Asian populations mapped to genomic regions with different patterns of LD. The first published GWAS for CAD, including a substantial number of South Asians, was by the C4D Consortium. Their discovery data set included ≈15 000 CAD cases; half of whom were of South Asian descent.22 Of the 11 previously reported common variants for CAD confirmed in this study, the effect was directionally consistent in European and South Asian populations. However, the OR for several of these, including 9p21.3 and SORT1 (encoding sortilin-1 and related to lipid metabolism), was somewhat lower in the South Asian studies. The recent 1000 Genomes–based meta-analysis included a small number of South Asian (13%) and East Asian (7%) subjects but did not report on ethnic-specific effects.25 In summary, despite smaller data sets, the directional effects of CAD risk alleles identified in European populations on CAD risk in South Asians are generally concordant. In contrast to a similar effect size of CAD risk alleles in East Asian and European populations, for many, the effect size is apparently attenuated in South Asians, possibly not only because of the interaction with unknown genetic or environmental factors but also because the causal variant(s) may be inadequately tagged by markers present on available genotyping arrays, resulting in blunted genetic effects.

In contrast to the findings in East and South Asians, the majority of CAD-associated loci (an exception being rs599839 at the SORT1 locus)35 identified in European populations have failed to replicate or shown considerably reduced effect size in black populations.34 This is despite the high prevalence of CAD among blacks and the potential advantage of interrogating their shorter LD blocks for fine mapping of previously identified CAD loci. Two signals previously reported for CAD at the 9p21.3 locus36,37 did not achieve replication in independent black data sets, and other signals for CAD have not been identified. In the Population Architecture Using Genomics and Epidemiology (PAGE) study, a consortium of multiancestry, population-based studies, 25% of tag SNPs identified in European GWAS had significantly different effect sizes in black cohorts.38 This might imply limited sharing of causal variants between Europeans and Africans when compared with other ethnicities. Given the lower level of LD in African populations, the index SNP identified in European studies may simply fail to tag potentially shared casual variants.34 However, replication has been achieved for signals associated with discrete CAD risk factors.37 It is possible that the genetic risk of CAD in blacks is related more strongly to the genetic contribution to prevalent risk factors, including hypertension and obesity.39 Given that multiple genetic variants of small effect size are believed to account for much of the heritability of CAD in Europeans, these are likely to be greater in number and more difficult to detect in populations of African descent. Here, it should be noted that the sample sizes of these studies in blacks are of smaller magnitudes than the sample sizes of the studies involving individuals of other ancestries, thus limiting statistical power.

Mendelian Randomization

Epidemiological studies have identified a large number of biomarkers that are associated with CAD. However, 2 of the most important problems of observational epidemiology are confounding and reverse causation. These factors limit the ability of these types of studies to identify causality of a biomarker or a risk factor. To circumvent confounding and reverse causation, a growing number of epidemiologists are turning to the Mendelian randomization (MR) method, a method that can be likened to the randomized controlled trial (RCT). This method that combines genetic and observational data takes advantage of the random assortment of genetic variants (=alleles) at conception; therefore, by studying common genetic variants that associate with the exposure variable of interest (eg, low-density lipoprotein [LDL] cholesterol [LDL-C]), reverse causation and most confounding can be avoided. The methodology is based on a simple tenet—if a biomarker has a causal association with a disease, the genetic determinants of the biomarker will also associate with disease risk.40 MR has limitations that are shared with RCTs, and one of the most important of these is the lack of pleiotropy, that is, the genetic variant(s) in question must influence only the biomarker of interest. This is not always the case for plasma lipid traits, where pleiotropic effects are evident for several genes, including CETP, LPL, and APOA5. Using MR, major advances have been made in determining the causal associations between plasma levels of lipoprotein(a), LDL-C, and triglycerides (as a marker of remnant cholesterol) and risk of CAD, whereas C-reactive protein (CRP) and high-density lipoprotein (HDL) cholesterol, despite both being robust risk markers, have not been shown to be causal (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Methodology is based on the tenet that if the biomarker has a causal association with disease, the genetic determinants of the biomarker will also associate with disease risk. A, If evidence #1 to #3 are all documented robustly, the interpretation is that the data are compatible with a causal relationship. B, If evidence #1 and #2 are documented robustly, but the genetic determinants of the biomarker do not associate with disease risk, the interpretation is that the association is noncausal. Using Mendelian randomization, major advances have been made in determining the causal associations between plasma levels of lipoprotein(a), low-density lipoprotein (LDL) cholesterol, triglycerides (TG; as a marker of remnant cholesterol), and body mass index (as a surrogate for obesity) with risk of coronary artery disease (CAD). In contrast, C-reactive protein, Lp-PLA2, high-density lipoprotein (HDL) cholesterol, fibrinogen, and homocysteine, despite being robust risk markers, have not been shown to be causal.

Elevated levels of lipoprotein(a) are associated with increased risk of CAD, and common copy number variants and SNPs in the LPA gene, which associate with increased lipoprotein(a) levels, cause an increased risk of CAD41–43 and of aortic valve stenosis.44,45 Although the exact mechanisms are not clear,46 these data suggest that apolipoprotein(a) is directly causal and therefore a potential drug target.

That elevated levels of LDL-C are causally associated with an increased risk of CAD is evident from familial hypercholesterolemia because of mutations in the LDLR. Genetic variants at the PCSK9, NPC1L1, and HMGCR loci uniquely associate with plasma concentrations of LDL-C and are therefore also predictive of CAD risk. As originally reported by Abifadel et al,47 gain-of-function mutations in PCSK9 cause autosomal dominant familial hypercholesterolemia. Cohen et al48 later reported that loss-of-function mutations in PCSK9 were associated with reduced plasma concentrations of LDL-C and lower risk of CAD, establishing PCSK9 as a relevant new drug target for lowering LDL-C levels. Ezetimibe reduces LDL-C levels by inhibiting Niemann–Pick C1-like protein1 (NPC1L1), a transporter that in humans is responsible for cholesterol uptake from the intestine into enterocytes and from bile into hepatocytes. Despite this, ezetimibe has only recently been shown to reduce cardiovascular risk.49 The Myocardial Infarction Genetics Consortium investigators sequenced NPC1L1 in 7364 CAD cases and 14 728 controls and identified 34 loss-of-function mutations. One of these, p.Arg406X, in a much larger replication study was found to be associated with a 10% lower LDL-C and a 50% decrease in CAD risk.50 Similarly, Lauridsen et al51, in a single-center study of the general population, included 67 385 individuals; of them, 5255 and 3886 developed incident ischemic vascular disease and symptomatic gallstone disease, respectively. Using a genetic score of common variants in NPC1L1, mimicking the effect of ezetimibe, they showed that these variants were associated with lifelong, stepwise reductions in LDL-C levels of ≤3.5%, with a corresponding 18% reduction in risk of CVD and a 22% increase in risk of symptomatic gallstone disease. The study, therefore, suggested that a biologically plausible long-term side effect of ezetimibe treatment might be an increased risk of symptomatic gallstone disease. Finally, Ference et al52 in a study of 108 376 subjects in 14 clinical trials reported that common genetic variants associated with each of NPC1L1 and HMGCR conferred a reduction in LDL-C of 2.4 and 2.9 mg/dL and a respective 4.8% and 5.3% lower CAD risk. Because PCSK9, NPC1L1, and HMGCR regulate LDL but do not exhibit effects on other lipid and nonlipid parameters, such studies strongly support a causative relationship between plasma concentrations of LDL-C and CAD. Importantly, multiple variants associated with LDL-C concentrations, that is, in PCSK948,53 and NPC1L150,51 genes, are more strongly associated with CAD than are associated differences in measured LDL-C or the effect of LDL-C reduction in the statin (RCTs). This is presumably because genetic effects encompass the lifetime exposure to LDL-C (Table 2).52,54

View this table:
  • View inline
  • View popup
Table 2.

Common Genetic Terminology

The role of plasma triglycerides as an independent risk factor of CAD was debated for many years. However, genetic studies have lent credence to the hypothesis that triglyceride-rich lipoproteins or their remnants have a causative role in atherosclerosis.55 The major determinant of plasma triglyceride metabolism is lipoprotein lipase, and genetic variants that decrease LPL function confer increased cardiovascular risk54,56–58 and all-cause mortality.54,59 LPL activity is increased by ApoA5 and inhibited by ApoC3 and the angiopoietin-like proteins 3 and 4. Loss-of-function mutations in APOC360,61 are associated with lower plasma triglycerides and CAD risk, whereas loss-of-function mutations in APOA5 have opposite effects.62 In a collaborative analysis, including 20 842 individuals with CAD and 35 206 controls, Sarwar et al63 reported that a common promoter polymorphism (–1131T>C; rs662799) in APOA5 was associated with CAD with an allele-specific OR of 1.18 directionally similar but quantitatively greater than the effects on plasma triglycerides. Similarly, Jørgensen et al64 found that genotype combinations of 3 common variants in APOA5 associated with increases in nonfasting triglycerides and calculated remnant cholesterol of 1.10 and 0.40 mmol/L, respectively and with corresponding ORs for myocardial infarction of 1.87 (1.25–2.81).

Essential for successful MR studies is the selection of genetic variants without pleiotropic effects. The major difficulty in studying raised concentrations of triglycerides or remnant cholesterol is the inverse association with HDL cholesterol concentrations.55 However, a MR study with genetic variants in several candidate genes that affect the concentrations of remnant cholesterol or HDL cholesterol or both showed that an increase of 1 mmol/L in remnant cholesterol was associated with a 2.8× increased risk of ischemic heart disease that was not attributable to lower HDL cholesterol concentrations.65 A recent GWAS also supports that variants associated with high concentrations of triglycerides are causally associated with CAD, after adjustment for HDL cholesterol.66 These 2 studies62,65,66 also showed that genetically low HDL cholesterol was unrelated to cardiovascular risk, in agreement with several previous studies essentially using an MR approach to test causality for HDL cholesterol.60–65 Because triglycerides can be degraded by most cells but cholesterol cannot, the cholesterol content of triglyceride-rich remnant lipoproteins (remnant cholesterol) is more likely to be the cause of atherosclerosis and cardiovascular disease rather than raised triglycerides. Remnant lipoproteins can, like LDL, enter and be trapped in the arterial intima simply because of their size and possibly via attachment to extracellular proteoglycans.55 Taken together, genetic studies strongly support that triglyceride-rich lipoproteins and remnant cholesterol are causal risk factors of CAD and all-cause mortality.

As noted above, MR studies have not supported a direct protective function of HDL cholesterol levels against CAD. Apolipoprotein A-I is the major protein on HDL, but common variants in APOA1 associated with low HDL cholesterol are not associated with an increased risk of CAD.67 For the effect of rare variants on CAD risk, the picture is complicated by the fact that some rare variants in APOA1 that associate with low HDL cholesterol, cause amyloidosis, and this, in addition to other symptoms, may manifest as CAD due to small vessel disease, increased intima media thickness, or in later stages as cardiomyopathy. Haase et al68,69 resequenced the APOA1 gene in >10 000 individuals, genotyped the identified variants in >55 000 individuals from the general population, and reported that the apparent increased risk associated with nonsynonymous mutations in APOA1 became insignificant when variants previously associated with amyloidosis were removed from the analysis. In support, mutations in APOA1 reported to associate with endothelial dysfunction, increased arterial wall thickness, and premature coronary heart disease70 have more recently been shown to cause systemic amyloidosis.71

For other biomarkers, MR studies have provided important insights relevant to drug targets, drug discovery, and potential long-term side effects of drugs. Although high-sensitivity CRP is a robust biomarker for CAD risk and response to stain therapy, neither common genetic variants in the CRP gene associated with substantial increases in CRP levels in the general population72 nor rare exonic variants associated with CRP levels73 associate with CAD risk, demonstrating that CRP is not a causal risk factor and hence not a relevant drug target. Similarly, although data from epidemiological and clinical studies supported a potentially important role of lipoprotein-associated phospholipase A2 in atherosclerosis and its sequelae,74,75 the genetic variants near PLA2G7 and CETP associated with LP-PLA2 levels and activity did not confer CAD risk.76,77 In accord with these findings, the results of phase III randomized controlled trials of inhibitors of these enzymes (varespladib78 and darapladib79) were also negative. A closer inspection of MR data before drug design and initiation of clinical trials could, thus, help to mitigate the high costs of drug development. Conversely, 3 of 4 CETP inhibitors either have failed because of adverse events (torcetrapib) or have been stopped because of futility (dalcetrapib and evacetrapib). Nevertheless, common genetic variants in CETP associated with reduced mass and activity are associated with increased HDL cholesterol, smaller decreases in LDL-C and triglycerides and, in the Copenhagen Heart Study, corresponding stepwise reductions in risk of all ischemic end points and all-cause mortality80 consistent with other reports.81–83 However, the effects of small molecule inhibition of CETP are not analogous to the small changes in CETP concentrations because of common genetic variants. Statin therapy lowers CETP by ≈20%,84 and as reported by Kuivenhoven et al,85 individuals with a common CETP polymorphism associated with higher CETP levels showed reduced progression of atherosclerosis when treated with pravastatin, whereas those with genetically low CETP concentrations did not, suggesting that there may be an optimal window of CETP activity.86

Utility of a Genetic Risk Score for Risk Assessment and Treatment Decisions

Although the effect of the identified susceptibility variants of CAD is individually small, their effects are independent and additive. These can be incorporated into a genetic risk score (GRS) consisting of the number of risk alleles adjusted for their individual effect size. In an analysis performed in 2 prospective cohorts, Whitehall II (WHII; n=5059) and the British Women’s Heart and Health Study (BWHHS; n=3414), individuals in the top versus bottom quintile of an LDL-C GRS consisting of 23 SNPs had a higher risk of CAD (WHII: OR=1.43; BWHHS: OR=1.31).87 After adjusting for LDL-C levels, this association was completely attenuated in WHII but not in BWHHS. The value of a GRS for CAD risk prediction beyond conventional risk factors has improved beyond previous studies considering a small number of risk variants88,89 beyond those related to plasma lipid traits to more recent analyses incorporating a more comprehensive list of recently identified CAD loci.90–92

Tikkanen et al92 constructed a GRS consisting of 28 CAD genetic variants and in 24 124 participants, in 4 population-based, prospective cohorts, determined its association with incident cardiovascular disease events for a mean 12-year follow-up period. Compared with conventional risk factors and family history alone, the GRS improved CAD risk discrimination (C index, 0.856 versus 0.851; P=0.0002). More recently, Mega et al93 evaluated the association of a GRS based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors in a community-based cohort study (48 421 individuals in the Malmo Diet and Cancer Study) and 4 RCTs of statin therapy, in primary (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER] and Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]) and secondary prevention (Cholesterol and Recurrent Events [CARE] and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Trials [PROVE IT-TIMI 22]) populations. Their major findings were that the multivariable adjusted hazard ratio for CAD was directly related to the GRS (hazard ratio, 1.72 for individuals in the highest versus the lowest GRS quintile) and that in the statin RCTs, both relative and absolute risk reductions were 3-fold greater in individuals in the highest genetic risk category, with highly significant effects on the number needed to treat. Thus, a GRS can provide important information on future CAD risk beyond traditional risk factors and may have both clinical and economic values in identifying those individuals who will benefit most from the early application of various disease-deferring therapies, including statin treatment.

Interrogation of Rare Coding Variants Contributing to CAD

Overall, the most recent GWAS analysis strongly supports the conclusion that genetic susceptibility to CAD is largely derived from the effect of multiple common SNPs of small effect size.25 However, this analysis was not able to interrogate rare variants present in >1 in 200 individuals, including nonsynonymous mutations in genes of relevance to CAD. Earlier studies that entailed only limited resequencing of candidate regions of the genome in CAD kindreds reported various rare mutations or copy number variants associated with CAD but for most replication has not been achieved.94 A 21-bp (7 amino acids) deletion in MEF2A was associated with apparent autosomal dominant CAD in 1 large kindred,95 but this was not confirmed in other studies, including the one involving 2 extended families bearing the same copy number variant.96

A comprehensive approach to identify and classify coding variants linked to human disease is whole-exome sequencing. This has yielded important findings for Mendelian disease particularly when family members were also available.97 It has also shown utility for the genetic diagnosis of various cardiomyopathies and cardiac conduction disorders.98 With reference to CAD, the Myocardial Infarction Genetics Consortium Exome Sequencing Project reported on whole-exome sequencing efforts in ≈11 000 individuals. Of note, the identified coding variants were limited to genes relevant to lipoprotein metabolism, including LDLR, APOA5, APOC3, and NPC1L150,60,62 and for which there was a large body of pre-existing information. This finding was somewhat disappointing but did provide further credence to the relevance of triglyceride metabolism to atherosclerosis55,61,63–65 and the validity of NPC1L1 as a drug target.49,51,99 Given the perceived need for large sample sizes and subsequent replication, the sample included CAD cases with limited phenotypes, such as acute myocardial infarction without angiographic documentation of disease burden, and controls who may have harbored a burden of nonobstructive atherosclerosis. The inability to follow up on rare variants of high effect size in family members with and without CAD may also have limited the ability to detect novel mutations linked to atherosclerosis. Importantly, studies to date have been significantly underpowered. Recent stimulation analyses indicate that tens of thousands of individuals will be required to confidently detect or exclude rare variant signals at complex disease loci, such as CAD.100

Beyond the Single SNP

Despite the recent success of GWASs, close to 80% of the estimated heritability of CAD remains unknown. Some of this missing heritability may be because of gene environment interaction101 where the effect of a given genetic variant is only manifest in the presence of a modifier, such as obesity or cigarette smoking. For example, the effect of common risk alleles for elevated plasma triglycerides was markedly attenuated in lean versus obese individuals.102 Epistasis is a statistical interaction between ≥2 genetic loci where the effects are nonadditive and has been hypothesized to play an important role in the genetic determination of complex diseases, such as CAD. Epistasis on a genome-wide level has proven challenging because of the requirement for individual genotype data, computational power required for a large number of pair-wise or high-order tests, and the need to correct for multiple testing. However, filtering to consider only those regions with potential biological interaction reduces the necessity for high computational power and the burden of multiple testing correction. We recently reported that SMAD3 is a necessary factor for transforming growth factor-β–mediated stimulation of mRNA and protein expression of type IV collagen genes in human vascular smooth muscle cells and demonstrated a statistical interaction between the COL4A1/COL4A2 locus and the SMAD3 locus by performing pair-wise tests between SNPs at the 2 loci.103

It is also likely that many more common variants are linked to CAD but have not achieved genome-wide significance in GWAS because of small effect size or low allele frequency and insufficient sample size. However, on the basis of the premise that clinically informative polymorphisms related to complex disease occur in systems of closely interacting genes,104 even weakly associated variants may provide important information on the biological basis of disease when such variants cluster within a common functional module or a pathway.105 Thus, novel insights into the genetic architecture of CAD can be obtained by interpreting genetic findings in the context of biological processes and functional interactions among genes.

A modified version of gene-set enrichment analysis, developed for the interrogation of gene expression data,106 was designed by Wang et al107 for the analysis of genome-wide SNP associations, and other gene-set enrichment analysis methods have been more recently applied to GWAS data.108–112 These analytic algorithms seek to identify a sets of genes whose variants collectively demonstrate strong association with a trait of interest even if the component SNPs individually exhibit relatively modest or nonsignificant association.105 To identify novel associations between established biological mechanisms and CAD, we recently performed a 2-stage pathway–based gene-set enrichment analysis of 16 GWAS data sets for CAD that included >25 000 subjects with CAD and >66 000 controls105 using the i-GSEA4GWAS tool112 and the Reactome pathway database.113 A total of 32 of 639 Reactome pathways tested demonstrated convincing association with CAD. These resided in core biological processes and included pathways relevant to extracellular matrix integrity, innate immunity, axon guidance, and signaling by platelet-derived growth factor, NOTCH, and the transforming growth factor-β–SMAD receptor complex. Importantly, many of these pathways were shown to have strengths of association comparable with those observed in lipid transport pathways.105

Systems Genetics Approach to Understanding the Genetic Basis of CAD

A further extension of the pathway approach is the interrogation of molecular networks that underlie the complex architecture of complex disease.114 A molecular network is based on interactions among diverse molecules, including genes, proteins, and metabolites. These can include interactions between proteins, effects on gene regulation, coexpression, and various functional interactions. In general, genes associated with the same or similar disorders tend to occupy similar molecular networks through physical or functional modules.115,116 Furthermore, this approach indicates that disease-related genes exhibit network connectivity and network centrality properties that are distinct from other genes.116

Thus, interrogation of molecular networks provides additional information on interactions among gene subsets within a given pathway and highlights potentially important interactions between components of different biological pathways. In the study of Ghosh et al,105 network analysis of unique genes within the replicated pathways not only further confirmed the known processes, such as lipid metabolism, but also revealed many interconnected functional and topologically interacting modules representing novel associations, for example, the semaphorin-regulated axonal guidance pathway. The axon guidance pathways modulate diverse biological phenomena, including cellular adhesion, migration, proliferation, differentiation, survival, and synaptic plasticity, through the participation of highly conserved families of guidance molecules, including netrins, slits, semaphorins, and ephrins, and their cognate receptors117 and members of these pathways have been highlighted in many recent reports related to macrophage migration,118 expression of inflammatory markers and M2 signals in atherosclerotic plaque,119 and chemokine-directed migration of human monocytes.120,121 Network centrality analysis further identified genes (eg, NCAM1, FYN, and FURIN) likely to play critical roles in the maintenance and functioning of several of the replicated pathways.

From Locus to Function

Despite the success of recent GWASs, there has been limited progress in understanding the function of the multiple risk loci identified. Notably, the majority of signals for CAD identified by the GWAS approach are in noncoding regions of the genome. This is not surprising, given that 99% of the genome is nonprotein coding. Nonetheless, ≈10% of this region is under purifying selection,122 implying important functional effects. These regions include noncoding RNAs that may influence gene transcription through multiple mechanisms,123 active promoter and enhancers, regions affecting histone acetylation and deacetylation and chromatin remodeling,124 susceptibility to DNA methylation, and micro-RNAs and micro-RNA binding sites.

The GWAS-identified polymorphisms are themselves rarely causal but rather in LD with a neighboring or even distal causal polymorphism. Most of the CAD-associated loci identified by GWASs span several kilobases, and some of these may encompass multiple causative variants in ≥1 genes. For common variants, fine-mapping approaches can be limited by large blocks of LD. As an example, the 9p21.3 risk locus encompasses multiple SNPs in tight LD. Dense resequencing failed to identify less common genetic variants with a larger effect size than the original GWAS SNPs.125 As reported by the 1000 Genomes Consortium, several CAD loci contain >1 independent signal.25 For example, 7 independent false discovery rate (q<0.05) SNPs were identified at the COL4A1/COL4A2 locus and 5 in the CDKN2BAS (9p21.3) region with 1 uncommon SNP, rs7855162 (MAF, 0.03), exhibiting a higher effect size than the index SNP.25

It is often not fully appreciated that although the association is at the level of genomic DNA, the relevance may be restricted to a particular tissue or organ. An expression quantitative trait locus (eQTL) effect, that is, an effect on mRNA expression on a nearby (cis-eQTL) or distant (trans-eQTL) gene, provides strong evidence for a functional effect of a given SNP. However, recent studies have shown that some eQTLs are shared among tissues, whereas others are tissue specific. Hence, interrogating eQTL databases, for example,126 Genotype Tissue expression and 127 SNP and CNV Annotation database, requires careful consideration of the cell type or tissue of interest.128 Finally, it must be acknowledged that the direct contribution of any given locus could be temporally restricted, for instance, early transient activation followed by sustained epigenetic effects.

The majority of common CAD-associated variants exhibit small individual effects on disease risk, and many are likely to exert their effects by altering promoter or enhancer activity. As a complementary approach to eQTL analysis, public databases, generated by the Encyclopedia of DNA Elements129 and Roadmap Epigenomics projects,130 genome-wide chromatin profiles of histone modifications, data on transcription factor–binding sites, and chromatin immunoprecipitation sequencing data131 can be used to identify specific functional regulatory elements.132 H3K4me3 denotes active promoters, H3K4me1 denotes enhancers, and H3K4me2, as well as most histone deacetylations, denotes both promoter and enhancer regions.133 DNase I hypersensitive sites are also a mark of open chromatin regions containing promoters and enhancers.134 Assay for transposase-accessible chromatin with high-throughput sequencing is a useful method for measuring chromatin accessibility genome wide.135 An important caveat is that these analyses require genome-wide chromatin data from a relevant cell type.136 These approaches to the identification of regulatory sequences can be followed up by more specific methodologies appropriate to the characteristics of the risk locus in the cell or tissue of interest. Thus, it can first be determined whether a risk locus is likely to harbor functional cis-acting regulatory modules whose activity is altered by an SNP in close LD with a particular risk variant before standard molecular biology approaches in the laboratory (Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

A, Typical Manhattan plot of a significant locus for coronary artery disease (CAD) identified in a meta-analysis of genome-wide association study (GWAS) for myocardial infarction (MI)/CAD. B, Visualization of the various linkage disequilibrium (LD) blocks in the closest gene using the Haploview software and linkage data taken from the 1000 Genomes Browser. C, UCSC genome browser annotation and Encyclopedia of DNA Elements (ENCODE) project data for the region bearing the lead single-nucleotide polymorphisms (SNPs), including chromatin regulatory features, such as DNase hypersensitivity sites, histone modifications (H3K4me1, H3K4me3, and H3K27ac), and predicted transcription factor binding from chromatin immunoprecipitation sequencing (ChIP-Seq) data. D, Interrogation of publically available databases, such HaploReg (motif analysis), RegulomeDB (a database that annotates SNPs with known and predicted regulatory elements in noncoding regions of the genomes), SCAN (SNP and CNV Annotation database; a database of genetic and genomic data with online methodology for mining these data), Genotype Tissue expression (GTex), and other expression quantitative trait locus (eQTL) databases, can provide further information relevant to function. E, Finally, extensive laboratory analyses, including enhancer and promoter assays, allele-specific ChIP, allele-specific expression analyses, and eQTL analyses in cell or tissue of relevance to CAD, is necessary to identify and molecularly characterize the functional variant underlying the GWAS signal.

The poster child for this approach was the identification of a previously unknown role for sortilin-1 in lipoprotein metabolism. Four common GWAS-identified SNPs associated with LDL-C and CAD lie in a noncoding DNA region on chromosome 1p31 between 2 genes, CELSR2 and PSRC1, and downstream of SORT1. In a series of elegant studies, including primary human hepatocytes, Musunuru et al137 demonstrated that these SNPs have the strongest hepatocyte eQTL effect for SORT1 and that one of these, rs12740374, creates a C/EBP (CCAAT/enhancer binding protein) transcription factor–binding site and alters the hepatic expression of SORT1 gene, encoding sortilin-1. In further studies in the mouse, genetically increased hepatic sortilin expression was shown to both reduce hepatic APOB secretion and increase LDL catabolism, providing dual mechanisms for the strong association between increased hepatic sortilin-1 expression and reduced plasma LDL-C levels in humans.138

In another recent investigation of GWAS significant loci, Sazonova et al139 used a complex series of bioinformatic, molecular, cell biology, and system genetic approaches to show that the transcription factor, TCF21, regulates a transcriptional network linking multiple independent CAD loci. The same group demonstrated that TCF21 regulates the development of the epicardial progenitor cells that give risk to smooth muscle cells that contribute to the fibrous cap.140 Similar approaches have provided new insight into the roles of PHACTR1141 and ADAMTS7142 in atherosclerosis. ADAMTS7 plays a role in the regulation of vascular smooth muscle cell migration, and Bauer et al143 recently demonstrated that Adamsts7−/− mice were protected from atherosclerosis on an Ldlr−/− or Apoe−/− background and showed reduced neointimal formation after femoral wire injury and that Adamsts7−/− vascular smooth muscle cells showed reduced migration in the setting of tumor necrosis factor-α stimulation, consistent with a proatherogenic effect of ADAMTS7.

Summary

The past decade of research has provided a broader understanding of the genetic architecture of CAD and demonstrates that the genetic basis of CAD largely derives from the cumulative effect of multiple common risk alleles individually of small effect size rather than rare variants with large effects on CAD risk. Although traditional risk factors remain important, application of these data using a systems genetics approach has pointed to substantial roles for genes and pathways relevant to vessel wall biology and immune function. A major priority is to apply high-throughput methodology to understand at the molecular and cellular levels the function of each of the novel loci; the majority of which are in noncoding regions of the genome. Beyond functional insight into disease mechanisms, these data have proven clinical utility for interrogation of biomarker causality and drug discovery, through MR, creation of a GRS with predictive power to better identify those individuals who will benefit most from statin therapy.

Sources of Funding

This study was supported by Canadian Institutes of Health Research MOP-136936 and Heart and Stroke Foundation of Canada BR-7519 and T-7268 (to R. McPherson).

Disclosures

R. McPherson has received funding from Merck, Pfizer, Sanofi, and Amgen. A. Tybjaerg-Hansen has received honoraria from Eli Lilly and LGC Genomics.

Footnotes

  • Circulation Research Compendium on Atherosclerosis

    Atherosclerosis: Successes, Surprises, and Future Challenges

    Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease

    Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New From Epidemiology, Genetics, and Biology

    Genetics of Coronary Artery Disease

    Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis

    From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease

    Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?

    Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis

    Macrophages and Dendritic Cells: Partners in Atherogenesis

    Macrophage Phenotype and Function in Different Stages of Atherosclerosis

    Adaptive Response of T and B Cells in Atherosclerosis

    Microdomains, Inflammation, and Atherosclerosis

    Vascular Smooth Muscle Cells in Atherosclerosis

    MicroRNA Regulation of Atherosclerosis

    The Success Story of LDL Cholesterol Lowering

    From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

    Imaging Atherosclerosis

    Peter Libby, Karin E. Bornfeldt, and Alan R. Tall, Editors

  • Nonstandard Abbreviations and Acronyms
    BWHHS
    British Women’s Heart and Health Study
    CAD
    coronary artery disease
    CARDIoGRAM
    Coronary Artery Disease Genome-Wide Replication and Meta-Analysis
    CRP
    C-reactive protein
    eQTL
    expression quantitative trait locus
    GRS
    genetic risk score
    GWAS
    genome-wide association study
    HDL
    high-density lipoprotein
    LD
    linkage disequilibrium
    LDL
    low-density lipoprotein
    LDL-C
    low-density lipoprotein cholesterol
    MAF
    minor allele frequency
    MR
    Mendelian randomization
    NPC1L1
    Niemann–Pick C1-like protein1
    OR
    odds ratio
    PAGE
    Population Architecture Using Genomics and Epidemiology
    RCT
    randomized controlled trial
    SNP
    single-nucleotide polymorphism
    WHII
    Whitehall II

  • Received November 3, 2015.
  • Revision received December 28, 2015.
  • Accepted January 6, 2016.
  • © 2016 American Heart Association, Inc.

References

  1. 1.↵
    1. Vinkhuyzen AA,
    2. Wray NR,
    3. Yang J,
    4. Goddard ME,
    5. Visscher PM.
    Estimation and partition of heritability in human populations using whole-genome analysis methods. Annu Rev Genet. 2013;47:75–95. doi: 10.1146/annurev-genet-111212-133258.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lloyd-Jones DM,
    2. Nam BH,
    3. D’Agostino RB Sr.,
    4. Levy D,
    5. Murabito JM,
    6. Wang TJ,
    7. Wilson PW,
    8. O’Donnell CJ.
    Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204–2211. doi: 10.1001/jama.291.18.2204.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Zdravkovic S,
    2. Wienke A,
    3. Pedersen NL,
    4. Marenberg ME,
    5. Yashin AI,
    6. De Faire U.
    Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med. 2002;252:247–254.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Schunkert H,
    2. König IR,
    3. Kathiresan S,
    4. et al
    ; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–338. doi: 10.1038/ng.784.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. McPherson R.
    A gene-centric approach to elucidating cardiovascular risk. Circ Cardiovasc Genet. 2009;2:3–6. doi: 10.1161/CIRCGENETICS.109.848986.
    OpenUrlFREE Full Text
  6. 6.↵
    1. McPherson R,
    2. Pertsemlidis A,
    3. Kavaslar N,
    4. Stewart A,
    5. Roberts R,
    6. Cox DR,
    7. Hinds DA,
    8. Pennacchio LA,
    9. Tybjaerg-Hansen A,
    10. Folsom AR,
    11. Boerwinkle E,
    12. Hobbs HH,
    13. Cohen JC.
    A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491. doi: 10.1126/science.1142447.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Helgadottir A,
    2. Thorleifsson G,
    3. Manolescu A,
    4. et al
    . A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–1493. doi: 10.1126/science.1142842.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Samani NJ,
    2. Erdmann J,
    3. Hall AS,
    4. et al
    ; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–453. doi: 10.1056/NEJMoa072366.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Dandona S,
    2. Stewart AF,
    3. Chen L,
    4. Williams K,
    5. So D,
    6. O’Brien E,
    7. Glover C,
    8. Lemay M,
    9. Assogba O,
    10. Vo L,
    11. Wang YQ,
    12. Labinaz M,
    13. Wells GA,
    14. McPherson R,
    15. Roberts R.
    Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol. 2010;56:479–486. doi: 10.1016/j.jacc.2009.10.092.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Chan K,
    2. Patel RS,
    3. Newcombe P,
    4. et al
    . Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol. 2013;61:957–970. doi: 10.1016/j.jacc.2012.10.051.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ye S,
    2. Willeit J,
    3. Kronenberg F,
    4. Xu Q,
    5. Kiechl S.
    Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol. 2008;52:378–384. doi: 10.1016/j.jacc.2007.11.087.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Smith JG,
    2. Melander O,
    3. Lövkvist H,
    4. Hedblad B,
    5. Engström G,
    6. Nilsson P,
    7. Carlson J,
    8. Berglund G,
    9. Norrving B,
    10. Lindgren A.
    Common genetic variants on chromosome 9p21 confers risk of ischemic stroke: a large-scale genetic association study. Circ Cardiovasc Genet. 2009;2:159–164. doi: 10.1161/CIRCGENETICS.108.835173.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Anderson CD,
    2. Biffi A,
    3. Rost NS,
    4. Cortellini L,
    5. Furie KL,
    6. Rosand J.
    Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke. 2010;41:1123–1131. doi: 10.1161/STROKEAHA.110.580589.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Cluett C,
    2. McDermott MM,
    3. Guralnik J,
    4. Ferrucci L,
    5. Bandinelli S,
    6. Miljkovic I,
    7. Zmuda JM,
    8. Li R,
    9. Tranah G,
    10. Harris T,
    11. Rice N,
    12. Henley W,
    13. Frayling TM,
    14. Murray A,
    15. Melzer D.
    The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people. Circ Cardiovasc Genet. 2009;2:347–353. doi: 10.1161/CIRCGENETICS.108.825935.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Bown MJ,
    2. Braund PS,
    3. Thompson J,
    4. London NJ,
    5. Samani NJ,
    6. Sayers RD.
    Association between the coronary artery disease risk locus on chromosome 9p21.3 and abdominal aortic aneurysm. Circ Cardiovasc Genet. 2008;1:39–42. doi: 10.1161/CIRCGENETICS.108.789727.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Helgadottir A,
    2. Thorleifsson G,
    3. Magnusson KP,
    4. et al
    . The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–224. doi: 10.1038/ng.72.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Musunuru K,
    2. Post WS,
    3. Herzog W,
    4. et al
    . Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet. 2010;3:445–453. doi: 10.1161/CIRCGENETICS.109.923508.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Fan M,
    2. Dandona S,
    3. McPherson R,
    4. Allayee H,
    5. Hazen SL,
    6. Wells GA,
    7. Roberts R,
    8. Stewart AF.
    Two chromosome 9p21 haplotype blocks distinguish between coronary artery disease and myocardial infarction risk. Circ Cardiovasc Genet. 2013;6:372–380. doi: 10.1161/CIRCGENETICS.113.000104.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Ernst FD,
    2. Uhr K,
    3. Teumer A,
    4. Fanghänel J,
    5. Schulz S,
    6. Noack B,
    7. Gonzales J,
    8. Reichert S,
    9. Eickholz P,
    10. Holtfreter B,
    11. Meisel P,
    12. Linden GJ,
    13. Homuth G,
    14. Kocher T.
    Replication of the association of chromosomal region 9p21.3 with generalized aggressive periodontitis (gAgP) using an independent case-control cohort. BMC Med Genet. 2010;11:119. doi: 10.1186/1471-2350-11-119.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Schaefer AS,
    2. Richter GM,
    3. Groessner-Schreiber B,
    4. Noack B,
    5. Nothnagel M,
    6. El Mokhtari NE,
    7. Loos BG,
    8. Jepsen S,
    9. Schreiber S.
    Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. PLoS Genet. 2009;5:e1000378. doi: 10.1371/journal.pgen.1000378.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Kathiresan S,
    2. Voight BF,
    3. Purcell S,
    4. et al
    . Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–41. doi: 10.1038/ng.327.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Peden JF,
    2. Hopewell JC,
    3. Saleheen D,
    4. et al
    . A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339–44. doi: 10.1038/ng.782.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Deloukas P,
    2. Kanoni S,
    3. Willenborg C,
    4. et al
    . Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33. doi: 10.1038/ng.2480.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Trégouët DA,
    2. König IR,
    3. Erdmann J,
    4. et al
    ; Wellcome Trust Case Control Consortium; Cardiogenics Consortium. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–285. doi: 10.1038/ng.314.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Nikpay M,
    2. Goel A,
    3. Won HH,
    4. et al
    ; CARDIoGRAMplusC4D Consortium. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47:1121–1130. doi: 10.1038/ng.3396.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Yang J,
    2. Lee SH,
    3. Goddard ME,
    4. Visscher PM.
    GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88:76–82. doi: 10.1016/j.ajhg.2010.11.011.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Yang J,
    2. Ferreira T,
    3. Morris AP,
    4. Medland SE,
    5. Madden PA,
    6. Heath AC,
    7. Martin NG,
    8. Montgomery GW,
    9. Weedon MN,
    10. Loos RJ,
    11. Frayling TM,
    12. McCarthy MI,
    13. Hirschhorn JN,
    14. Goddard ME,
    15. Visscher PM
    ; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44:369–375, S1–S3. doi: 10.1038/ng.2213.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Maurano MT,
    2. Humbert R,
    3. Rynes E,
    4. et al
    . Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190–1195. doi: 10.1126/science.1222794.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Won HH,
    2. Natarajan P,
    3. Dobbyn A,
    4. Jordan DM,
    5. Roussos P,
    6. Lage K,
    7. Raychaudhuri S,
    8. Stahl E,
    9. Do R.
    Disproportionate contributions of select genomic compartments and cell types to genetic risk for coronary artery disease. PLoS Genet. 2015;11:e1005622. doi: 10.1371/journal.pgen.1005622.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Lonjou C,
    2. Zhang W,
    3. Collins A,
    4. Tapper WJ,
    5. Elahi E,
    6. Maniatis N,
    7. Morton NE.
    Linkage disequilibrium in human populations. Proc Natl Acad Sci U S A. 2003;100:6069–6074. doi: 10.1073/pnas.1031521100.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Campbell MC,
    2. Tishkoff SA.
    African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008;9:403–433. doi: 10.1146/annurev.genom.9.081307.164258.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Hinds DA,
    2. Stuve LL,
    3. Nilsen GB,
    4. Halperin E,
    5. Eskin E,
    6. Ballinger DG,
    7. Frazer KA,
    8. Cox DR.
    Whole-genome patterns of common DNA variation in three human populations. Science. 2005;307:1072–1079. doi: 10.1126/science.1105436.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Edwards SL,
    2. Beesley J,
    3. French JD,
    4. Dunning AM.
    Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet. 2013;93:779–797. doi: 10.1016/j.ajhg.2013.10.012.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Marigorta UM,
    2. Navarro A.
    High trans-ethnic replicability of GWAS results implies common causal variants. PLoS Genet. 2013;9:e1003566. doi: 10.1371/journal.pgen.1003566.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Franceschini N,
    2. Carty C,
    3. Bůzková P,
    4. et al
    . Association of genetic variants and incident coronary heart disease in multiethnic cohorts: the PAGE study. Circ Cardiovasc Genet. 2011;4:661–672. doi: 10.1161/CIRCGENETICS.111.960096.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Kral BG,
    2. Mathias RA,
    3. Suktitipat B,
    4. Ruczinski I,
    5. Vaidya D,
    6. Yanek LR,
    7. Quyyumi AA,
    8. Patel RS,
    9. Zafari AM,
    10. Vaccarino V,
    11. Hauser ER,
    12. Kraus WE,
    13. Becker LC,
    14. Becker DM.
    A common variant in the CDKN2B gene on chromosome 9p21 protects against coronary artery disease in Americans of African ancestry. J Hum Genet. 2011;56:224–229. doi: 10.1038/jhg.2010.171.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Lettre G,
    2. Palmer CD,
    3. Young T,
    4. et al
    . Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet. 2011;7:e1001300. doi: 10.1371/journal.pgen.1001300.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Carlson CS,
    2. Matise TC,
    3. North KE,
    4. et al
    ; PAGE Consortium. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol. 2013;11:e1001661. doi: 10.1371/journal.pbio.1001661.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Wojczynski MK,
    2. Li M,
    3. Bielak LF,
    4. et al
    . Genetics of coronary artery calcification among African Americans, a meta-analysis. BMC Med Genet. 2013;14:75. doi: 10.1186/1471-2350-14-75.
    OpenUrlPubMed
  40. 40.↵
    1. Evans DM,
    2. Davey Smith G.
    Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet. 2015;16:327–350. doi: 10.1146/annurev-genom-090314-050016.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Kamstrup PR,
    2. Tybjaerg-Hansen A,
    3. Steffensen R,
    4. Nordestgaard BG.
    Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339. doi: 10.1001/jama.2009.801.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Erqou S,
    2. Kaptoge S,
    3. Perry PL,
    4. Di AE,
    5. Thompson A,
    6. White IR,
    7. Marcovina SM,
    8. Collins R,
    9. Thompson SG,
    10. Danesh J.
    Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. doi: 10.1001/jama.2009.1063.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Clarke R,
    2. Peden JF,
    3. Hopewell JC,
    4. et al
    ; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528. doi: 10.1056/NEJMoa0902604.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Thanassoulis G,
    2. Campbell CY,
    3. Owens DS,
    4. et al
    ; CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512. doi: 10.1056/NEJMoa1109034.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Kamstrup PR,
    2. Tybjærg-Hansen A,
    3. Nordestgaard BG.
    Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–477. doi: 10.1016/j.jacc.2013.09.038.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Koschinsky ML,
    2. Boffa MB.
    Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Endocrinol Metab Clin North Am. 2014;43:949–962. doi: 10.1016/j.ecl.2014.08.002.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Abifadel M,
    2. Varret M,
    3. Rabès JP,
    4. et al
    . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156. doi: 10.1038/ng1161.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Cohen JC,
    2. Boerwinkle E,
    3. Mosley TH Jr.,
    4. Hobbs HH.
    Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. doi: 10.1056/NEJMoa054013.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Cannon CP,
    2. Blazing MA,
    3. Giugliano RP,
    4. et al
    ; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Stitziel NO,
    2. Won HH,
    3. Morrison AC,
    4. et al
    . Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072–2082. doi: 10.1056/NEJMoa1405386.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Lauridsen BK,
    2. Stender S,
    3. Frikke-Schmidt R,
    4. Nordestgaard BG,
    5. Tybjærg-Hansen A.
    Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J. 2015;36:1601–1608. doi: 10.1093/eurheartj/ehv108.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Ference BA,
    2. Majeed F,
    3. Penumetcha R,
    4. Flack JM,
    5. Brook RD.
    Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65:1552–1561. doi: 10.1016/j.jacc.2015.02.020.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Benn M,
    2. Nordestgaard BG,
    3. Grande P,
    4. Schnohr P,
    5. Tybjaerg-Hansen A.
    PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833–2842. doi: 10.1016/j.jacc.2010.02.044.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Ference BA,
    2. Yoo W,
    3. Alesh I,
    4. Mahajan N,
    5. Mirowska KK,
    6. Mewada A,
    7. Kahn J,
    8. Afonso L,
    9. Williams KA Sr.,
    10. Flack JM.
    Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–2639. doi: 10.1016/j.jacc.2012.09.017.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Nordestgaard BG,
    2. Varbo A.
    Triglycerides and cardiovascular disease. Lancet. 2014;384:626–635. doi: 10.1016/S0140-6736(14)61177-6.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Nordestgaard BG,
    2. Abildgaard S,
    3. Wittrup HH,
    4. Steffensen R,
    5. Jensen G,
    6. Tybjaerg-Hansen A.
    Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737–1744.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Wittrup HH,
    2. Tybjaerg-Hansen A,
    3. Abildgaard S,
    4. Steffensen R,
    5. Schnohr P,
    6. Nordestgaard BG.
    A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest. 1997;99:1606–1613. doi: 10.1172/JCI119323.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Wittrup HH,
    2. Tybjaerg-Hansen A,
    3. Nordestgaard BG.
    Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99:2901–2907.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Thomsen M,
    2. Varbo A,
    3. Tybjærg-Hansen A,
    4. Nordestgaard BG.
    Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem. 2014;60:737–746. doi: 10.1373/clinchem.2013.219881.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    1. Crosby J,
    2. Peloso GM,
    3. Auer PL,
    4. et al
    ; TG and HDL Working Group of the Exome Sequencing Project; National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–231. doi: 10.1056/NEJMoa1307095.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Jørgensen AB,
    2. Frikke-Schmidt R,
    3. Nordestgaard BG,
    4. Tybjærg-Hansen A.
    Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41. doi: 10.1056/NEJMoa1308027.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Do R,
    2. Stitziel NO,
    3. Won HH,
    4. et al
    ; NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518:102–106. doi: 10.1038/nature13917.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Sarwar N,
    2. Sandhu MS,
    3. Ricketts SL,
    4. et al
    . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–1639. doi: 10.1016/S0140-6736(10)60545-4.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Jørgensen AB,
    2. Frikke-Schmidt R,
    3. West AS,
    4. Grande P,
    5. Nordestgaard BG,
    6. Tybjærg-Hansen A.
    Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826–1833. doi: 10.1093/eurheartj/ehs431.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Varbo A,
    2. Benn M,
    3. Tybjærg-Hansen A,
    4. Jørgensen AB,
    5. Frikke-Schmidt R,
    6. Nordestgaard BG.
    Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–436. doi: 10.1016/j.jacc.2012.08.1026.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Do R,
    2. Willer CJ,
    3. Schmidt EM,
    4. et al
    . Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–1352. doi: 10.1038/ng.2795.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Haase CL,
    2. Tybjærg-Hansen A,
    3. Grande P,
    4. Frikke-Schmidt R.
    Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab. 2010;95:E500–E510. doi: 10.1210/jc.2010-0450.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Haase CL,
    2. Frikke-Schmidt R,
    3. Nordestgaard BG,
    4. Kateifides AK,
    5. Kardassis D,
    6. Nielsen LB,
    7. Andersen CB,
    8. Køber L,
    9. Johnsen AH,
    10. Grande P,
    11. Zannis VI,
    12. Tybjaerg-Hansen A.
    Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med. 2011;270:136–146. doi: 10.1111/j.1365-2796.2011.02381.x.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Haase CL,
    2. Frikke-Schmidt R,
    3. Nordestgaard BG,
    4. Tybjærg-Hansen A.
    Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet. 2012;8:e1003063. doi: 10.1371/journal.pgen.1003063.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Hovingh GK,
    2. Brownlie A,
    3. Bisoendial RJ,
    4. Dube MP,
    5. Levels JH,
    6. Petersen W,
    7. Dullaart RP,
    8. Stroes ES,
    9. Zwinderman AH,
    10. de Groot E,
    11. Hayden MR,
    12. Kuivenhoven JA,
    13. Kastelein JJ.
    A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol. 2004;44:1429–1435. doi: 10.1016/j.jacc.2004.06.070.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Hazenberg AJ,
    2. Dikkers FG,
    3. Hawkins PN,
    4. Bijzet J,
    5. Rowczenio D,
    6. Gilbertson J,
    7. Posthumus MD,
    8. Leijsma MK,
    9. Hazenberg BP.
    Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis. Laryngoscope. 2009;119:608–615. doi: 10.1002/lary.20106.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Zacho J,
    2. Tybjaerg-Hansen A,
    3. Jensen JS,
    4. Grande P,
    5. Sillesen H,
    6. Nordestgaard BG.
    Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–1908. doi: 10.1056/NEJMoa0707402.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Schick UM,
    2. Auer PL,
    3. Bis JC,
    4. et al
    ; Cohorts for Heart and Aging Research in Genomic Epidemiology; National Heart, Lung, and Blood Institute GO Exome Sequencing Project. Association of exome sequences with plasma C-reactive protein levels in >9000 participants. Hum Mol Genet. 2015;24:559–571. doi: 10.1093/hmg/ddu450.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Mallat Z,
    2. Lambeau G,
    3. Tedgui A.
    Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122:2183–2200. doi: 10.1161/CIRCULATIONAHA.110.936393.
    OpenUrlFREE Full Text
  75. 75.↵
    1. Thompson A,
    2. Gao P,
    3. Orfei L,
    4. et al
    . Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–1544. doi: 10.1016/S0140-6736(10)60319-4.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Casas JP,
    2. Ninio E,
    3. Panayiotou A,
    4. et al
    . PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation. 2010;121:2284–2293. doi: 10.1161/CIRCULATIONAHA.109.923383.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Holmes MV,
    2. Simon T,
    3. Exeter HJ,
    4. et al
    . Secretory phospholipase A(2)-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2013;62:1966–1976. doi: 10.1016/j.jacc.2013.06.044.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Nicholls SJ,
    2. Kastelein JJ,
    3. Schwartz GG,
    4. Bash D,
    5. Rosenson RS,
    6. Cavender MA,
    7. Brennan DM,
    8. Koenig W,
    9. Jukema JW,
    10. Nambi V,
    11. Wright RS,
    12. Menon V,
    13. Lincoff AM,
    14. Nissen SE
    ; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252–262. doi: 10.1001/jama.2013.282836.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. White HD,
    2. Held C,
    3. Stewart R,
    4. et al
    . Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702–1711. doi: 10.1056/NEJMoa1315878.
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. Johannsen TH,
    2. Frikke-Schmidt R,
    3. Schou J,
    4. Nordestgaard BG,
    5. Tybjærg-Hansen A.
    Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60:2041–2048. doi: 10.1016/j.jacc.2012.07.045.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Thompson A,
    2. Di Angelantonio E,
    3. Sarwar N,
    4. Erqou S,
    5. Saleheen D,
    6. Dullaart RP,
    7. Keavney B,
    8. Ye Z,
    9. Danesh J.
    Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–2788. doi: 10.1001/jama.299.23.2777.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. Ridker PM,
    2. Paré G,
    3. Parker AN,
    4. Zee RY,
    5. Miletich JP,
    6. Chasman DI.
    Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2:26–33. doi: 10.1161/CIRCGENETICS.108.817304.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Voight BF,
    2. Peloso GM,
    3. Orho-Melander M,
    4. et al
    . Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–580. doi: 10.1016/S0140-6736(12)60312-2.
    OpenUrlCrossRefPubMed
  84. 84.↵
    1. Inazu A,
    2. Koizumi J,
    3. Kajinami K,
    4. Kiyohar T,
    5. Chichibu K,
    6. Mabuchi H.
    Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis. 1999;145:405–413.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Kuivenhoven JA,
    2. Jukema JW,
    3. Zwinderman AH,
    4. de Knijff P,
    5. McPherson R,
    6. Bruschke AV,
    7. Lie KI,
    8. Kastelein JJ.
    The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338:86–93. doi: 10.1056/NEJM199801083380203.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Regieli JJ,
    2. Jukema JW,
    3. Grobbee DE,
    4. Kastelein JJ,
    5. Kuivenhoven JA,
    6. Zwinderman AH,
    7. van der Graaf Y,
    8. Bots ML,
    9. Doevendans PA.
    CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792–2799. doi: 10.1093/eurheartj/ehn465.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Shah S,
    2. Casas JP,
    3. Drenos F,
    4. et al
    . Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis. Circ Cardiovasc Genet. 2013;6:63–72. doi: 10.1161/CIRCGENETICS.112.963140.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Brautbar A,
    2. Ballantyne CM,
    3. Lawson K,
    4. Nambi V,
    5. Chambless L,
    6. Folsom AR,
    7. Willerson JT,
    8. Boerwinkle E.
    Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. Circ Cardiovasc Genet. 2009;2:279–285. doi: 10.1161/CIRCGENETICS.108.817338.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Davies RW,
    2. Dandona S,
    3. Stewart AF,
    4. Chen L,
    5. Ellis SG,
    6. Tang WH,
    7. Hazen SL,
    8. Roberts R,
    9. McPherson R,
    10. Wells GA.
    Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet. 2010;3:468–474. doi: 10.1161/CIRCGENETICS.110.946269.
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Ripatti S,
    2. Tikkanen E,
    3. Orho-Melander M,
    4. et al
    . A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–1400. doi: 10.1016/S0140-6736(10)61267-6.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Ganna A,
    2. Magnusson PK,
    3. Pedersen NL,
    4. de Faire U,
    5. Reilly M,
    6. Arnlöv J,
    7. Sundström J,
    8. Hamsten A,
    9. Ingelsson E.
    Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267–2272. doi: 10.1161/ATVBAHA.113.301218.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Tikkanen E,
    2. Havulinna AS,
    3. Palotie A,
    4. Salomaa V,
    5. Ripatti S.
    Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261–2266. doi: 10.1161/ATVBAHA.112.301120.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Mega JL,
    2. Stitziel NO,
    3. Smith JG,
    4. et al
    . Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264–2271. doi: 10.1016/S0140-6736(14)61730-X.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Casas JP,
    2. Cooper J,
    3. Miller GJ,
    4. Hingorani AD,
    5. Humphries SE.
    Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet. 2006;70:145–169. doi: 10.1111/j.1469-1809.2005.00241.x.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Wang L,
    2. Fan C,
    3. Topol SE,
    4. Topol EJ,
    5. Wang Q.
    Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–1581. doi: 10.1126/science.1088477.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Weng L,
    2. Kavaslar N,
    3. Ustaszewska A,
    4. Doelle H,
    5. Schackwitz W,
    6. Hébert S,
    7. Cohen JC,
    8. McPherson R,
    9. Pennacchio LA.
    Lack of MEF2A mutations in coronary artery disease. J Clin Invest. 2005;115:1016–1020. doi: 10.1172/JCI24186.
    OpenUrlCrossRefPubMed
  97. 97.↵
    1. Chong JX,
    2. Buckingham KJ,
    3. Jhangiani SN,
    4. et al
    ; Centers for Mendelian Genomics. The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities. Am J Hum Genet. 2015;97:199–215. doi: 10.1016/j.ajhg.2015.06.009.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Arndt AK,
    2. MacRae CA.
    Genetic testing in cardiovascular diseases. Curr Opin Cardiol. 2014;29:235–240. doi: 10.1097/HCO.0000000000000055.
    OpenUrlCrossRefPubMed
  99. 99.↵
    1. McPherson R,
    2. Hegele RA.
    Ezetimibe: rescued by randomization (clinical and Mendelian). Arterioscler Thromb Vasc Biol. 2015;35:e13–e15. doi: 10.1161/ATVBAHA.114.305012.
    OpenUrlFREE Full Text
  100. 100.↵
    1. Moutsianas L,
    2. Agarwala V,
    3. Fuchsberger C,
    4. Flannick J,
    5. Rivas MA,
    6. Gaulton KJ,
    7. Albers PK,
    8. McVean G,
    9. Boehnke M,
    10. Altshuler D,
    11. McCarthy MI
    ; GoT2D Consortium. The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. PLoS Genet. 2015;11:e1005165. doi: 10.1371/journal.pgen.1005165.
    OpenUrlCrossRefPubMed
  101. 101.↵
    1. Cole CB,
    2. Nikpay M,
    3. McPherson R.
    Gene-environment interaction in dyslipidemia. Curr Opin Lipidol. 2015;26:133–138. doi: 10.1097/MOL.0000000000000160.
    OpenUrlCrossRefPubMed
  102. 102.↵
    1. Cole CB,
    2. Nikpay M,
    3. Lau P,
    4. Stewart AF,
    5. Davies RW,
    6. Wells GA,
    7. Dent R,
    8. McPherson R.
    Adiposity significantly modifies genetic risk for dyslipidemia. J Lipid Res. 2014;55:2416–2422. doi: 10.1194/jlr.P052522.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Turner AW,
    2. Nikpay M,
    3. Silva A,
    4. Lau P,
    5. Martinuk A,
    6. Linseman TA,
    7. Soubeyrand S,
    8. McPherson R.
    Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease. Atherosclerosis. 2015;242:543–552. doi: 10.1016/j.atherosclerosis.2015.08.008.
    OpenUrlCrossRefPubMed
  104. 104.↵
    1. Jia P,
    2. Wang L,
    3. Fanous AH,
    4. Pato CN,
    5. Edwards TL,
    6. Zhao Z
    ; International Schizophrenia Consortium. Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol. 2012;8:e1002587. doi: 10.1371/journal.pcbi.1002587.
    OpenUrlCrossRefPubMed
  105. 105.↵
    1. Ghosh S,
    2. Vivar J,
    3. Nelson CP,
    4. et al
    . Systems genetics analysis of genome-wide association study reveals novel associations between key biological processes and coronary artery disease. Arterioscler Thromb Vasc Biol. 2015;35:1712–1722. doi: 10.1161/ATVBAHA.115.305513.
    OpenUrlAbstract/FREE Full Text
  106. 106.↵
    1. Subramanian A,
    2. Tamayo P,
    3. Mootha VK,
    4. Mukherjee S,
    5. Ebert BL,
    6. Gillette MA,
    7. Paulovich A,
    8. Pomeroy SL,
    9. Golub TR,
    10. Lander ES,
    11. Mesirov JP.
    Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102.
    OpenUrlAbstract/FREE Full Text
  107. 107.↵
    1. Wang K,
    2. Li M,
    3. Bucan M.
    Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet. 2007;81:1278–1283. doi: 10.1086/522374.
    OpenUrlCrossRefPubMed
  108. 108.↵
    1. Wang K,
    2. Li M,
    3. Hakonarson H.
    Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11:843–854. doi: 10.1038/nrg2884.
    OpenUrlCrossRefPubMed
  109. 109.↵
    1. Wang L,
    2. Jia P,
    3. Wolfinger RD,
    4. Chen X,
    5. Zhao Z.
    Gene set analysis of genome-wide association studies: methodological issues and perspectives. Genomics. 2011;98:1–8. doi: 10.1016/j.ygeno.2011.04.006.
    OpenUrlCrossRefPubMed
  110. 110.↵
    1. Segrè AV,
    2. Groop L,
    3. Mootha VK,
    4. Daly MJ,
    5. Altshuler D
    ; DIAGRAM Consortium; MAGIC Investigators. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010;6. doi: 10.1371/journal.pgen.1001058.
  111. 111.↵
    1. Nam D,
    2. Kim J,
    3. Kim SY,
    4. Kim S.
    GSA-SNP: a general approach for gene set analysis of polymorphisms. Nucleic Acids Res. 2010;38:W749–W754. doi: 10.1093/nar/gkq428.
    OpenUrlAbstract/FREE Full Text
  112. 112.↵
    1. Zhang K,
    2. Cui S,
    3. Chang S,
    4. Zhang L,
    5. Wang J.
    i-GSEA4GWAS: a web server for identification of pathways/gene sets associated with traits by applying an improved gene set enrichment analysis to genome-wide association study. Nucleic Acids Res. 2010;38:W90–W95. doi: 10.1093/nar/gkq324.
    OpenUrlAbstract/FREE Full Text
  113. 113.↵
    1. Matthews L,
    2. Gopinath G,
    3. Gillespie M,
    4. et al
    . Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009;37:D619–D622. doi: 10.1093/nar/gkn863.
    OpenUrlAbstract/FREE Full Text
  114. 114.↵
    1. Björkegren JL,
    2. Kovacic JC,
    3. Dudley JT,
    4. Schadt EE.
    Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol. 2015;65:830–845. doi: 10.1016/j.jacc.2014.12.033.
    OpenUrlCrossRefPubMed
  115. 115.↵
    1. Oti M,
    2. Brunner HG.
    The modular nature of genetic diseases. Clin Genet. 2007;71:1–11. doi: 10.1111/j.1399-0004.2006.00708.x.
    OpenUrlCrossRefPubMed
  116. 116.↵
    1. Feldman I,
    2. Rzhetsky A,
    3. Vitkup D.
    Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci U S A. 2008;105:4323–4328. doi: 10.1073/pnas.0701722105.
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Schmidt EF,
    2. Strittmatter SM.
    The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol. 2007;600:1–11. doi: 10.1007/978-0-387-70956-7_1.
    OpenUrlCrossRefPubMed
  118. 118.↵
    1. van Gils JM,
    2. Derby MC,
    3. Fernandes LR,
    4. et al
    . The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol. 2012;13:136–143. doi: 10.1038/ni.2205.
    OpenUrlCrossRefPubMed
  119. 119.↵
    1. Oksala N,
    2. Pärssinen J,
    3. Seppälä I,
    4. Raitoharju E,
    5. Kholova I,
    6. Ivana K,
    7. Hernesniemi J,
    8. Lyytikäinen LP,
    9. Levula M,
    10. Mäkelä KM,
    11. Sioris T,
    12. Kähönen M,
    13. Laaksonen R,
    14. Hytönen V,
    15. Lehtimäki T.
    Association of neuroimmune guidance cue netrin-1 and its chemorepulsive receptor UNC5B with atherosclerotic plaque expression signatures and stability in human(s): Tampere Vascular Study (TVS). Circ Cardiovasc Genet. 2013;6:579–587. doi: 10.1161/CIRCGENETICS.113.000141.
    OpenUrlAbstract/FREE Full Text
  120. 120.↵
    1. Wanschel A,
    2. Seibert T,
    3. Hewing B,
    4. Ramkhelawon B,
    5. Ray TD,
    6. van Gils JM,
    7. Rayner KJ,
    8. Feig JE,
    9. O’Brien ER,
    10. Fisher EA,
    11. Moore KJ.
    Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol. 2013;33:886–893. doi: 10.1161/ATVBAHA.112.300941.
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    1. van Gils JM,
    2. Ramkhelawon B,
    3. Fernandes L,
    4. Stewart MC,
    5. Guo L,
    6. Seibert T,
    7. Menezes GB,
    8. Cara DC,
    9. Chow C,
    10. Kinane TB,
    11. Fisher EA,
    12. Balcells M,
    13. Alvarez-Leite J,
    14. Lacy-Hulbert A,
    15. Moore KJ.
    Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler Thromb Vasc Biol. 2013;33:911–919. doi: 10.1161/ATVBAHA.112.301155.
    OpenUrlAbstract/FREE Full Text
  122. 122.↵
    1. Davydov EV,
    2. Goode DL,
    3. Sirota M,
    4. Cooper GM,
    5. Sidow A,
    6. Batzoglou S.
    Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol. 2010;6:e1001025. doi: 10.1371/journal.pcbi.1001025.
    OpenUrlCrossRefPubMed
  123. 123.↵
    1. Esteller M.
    Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–874. doi: 10.1038/nrg3074.
    OpenUrlCrossRefPubMed
  124. 124.↵
    1. Gillette TG,
    2. Hill JA.
    Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res. 2015;116:1245–1253. doi: 10.1161/CIRCRESAHA.116.303630.
    OpenUrlAbstract/FREE Full Text
  125. 125.↵
    1. Shea J,
    2. Agarwala V,
    3. Philippakis AA,
    4. Maguire J,
    5. Banks E,
    6. Depristo M,
    7. Thomson B,
    8. Guiducci C,
    9. Onofrio RC,
    10. Kathiresan S,
    11. Gabriel S,
    12. Burtt NP,
    13. Daly MJ,
    14. Groop L,
    15. Altshuler D
    ; Myocardial Infarction Genetics Consortium. Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet. 2011;43:801–805. doi: 10.1038/ng.871.
    OpenUrlCrossRefPubMed
  126. 126.↵
    1. Yang J,
    2. Huang T,
    3. Petralia F,
    4. Long Q,
    5. Zhang B,
    6. Argmann C,
    7. Zhao Y,
    8. Mobbs CV,
    9. Schadt EE,
    10. Zhu J,
    11. Tu Z
    ; GTEx Consortium. Synchronized age-related gene expression changes across multiple tissues in human and the link to complex diseases. Sci Rep. 2015;5:15145. doi: 10.1038/srep15145.
    OpenUrlCrossRefPubMed
  127. 127.↵
    1. Zhang W,
    2. Gamazon ER,
    3. Zhang X,
    4. Konkashbaev A,
    5. Liu C,
    6. Szilágyi KL,
    7. Dolan ME,
    8. Cox NJ.
    SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database (Oxford). 2015, 1–7. doi: 10.1093/database/bav025.
  128. 128.↵
    1. Brown CD,
    2. Mangravite LM,
    3. Engelhardt BE.
    Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs. PLoS Genet. 2013;9:e1003649. doi: 10.1371/journal.pgen.1003649.
    OpenUrlCrossRefPubMed
  129. 129.↵
    ENCODE Project Consortium. A user’s guide to the Encyclopedia of DNA Elements (ENCODE). PLoS Biol. 2011;9:e1001046. doi: 10.1371/journal.pbio.1001046.
    OpenUrlCrossRefPubMed
  130. 130.↵
    1. Chadwick LH.
    The NIH Roadmap Epigenomics Program data resource. Epigenomics. 2012;4:317–324. doi: 10.2217/epi.12.18.
    OpenUrlCrossRefPubMed
  131. 131.↵
    1. Park PJ.
    ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10:669–680. doi: 10.1038/nrg2641.
    OpenUrlCrossRefPubMed
  132. 132.↵
    1. Raychaudhuri S.
    Mapping rare and common causal alleles for complex human diseases. Cell. 2011;147:57–69. doi: 10.1016/j.cell.2011.09.011.
    OpenUrlCrossRefPubMed
  133. 133.↵
    1. Wang Z,
    2. Zang C,
    3. Rosenfeld JA,
    4. Schones DE,
    5. Barski A,
    6. Cuddapah S,
    7. Cui K,
    8. Roh TY,
    9. Peng W,
    10. Zhang MQ,
    11. Zhao K.
    Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897–903. doi: 10.1038/ng.154.
    OpenUrlCrossRefPubMed
  134. 134.↵
    1. Mercer TR,
    2. Edwards SL,
    3. Clark MB,
    4. Neph SJ,
    5. Wang H,
    6. Stergachis AB,
    7. John S,
    8. Sandstrom R,
    9. Li G,
    10. Sandhu KS,
    11. Ruan Y,
    12. Nielsen LK,
    13. Mattick JS,
    14. Stamatoyannopoulos JA.
    DNase I-hypersensitive exons colocalize with promoters and distal regulatory elements. Nat Genet. 2013;45:852–859. doi: 10.1038/ng.2677.
    OpenUrlCrossRefPubMed
  135. 135.↵
    1. Buenrostro JD,
    2. Wu B,
    3. Chang HY,
    4. Greenleaf WJ.
    ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr Protoc Mol Biol. 2015;109:21.29.1–21.29.9. doi: 10.1002/0471142727.mb2129s109.
    OpenUrlCrossRef
  136. 136.↵
    1. Boyle AP,
    2. Song L,
    3. Lee BK,
    4. London D,
    5. Keefe D,
    6. Birney E,
    7. Iyer VR,
    8. Crawford GE,
    9. Furey TS.
    High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells. Genome Res. 2011;21:456–464. doi: 10.1101/gr.112656.110.
    OpenUrlAbstract/FREE Full Text
  137. 137.↵
    1. Musunuru K,
    2. Strong A,
    3. Frank-Kamenetsky M,
    4. et al
    . From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714–719. doi: 10.1038/nature09266.
    OpenUrlCrossRefPubMed
  138. 138.↵
    1. Strong A,
    2. Ding Q,
    3. Edmondson AC,
    4. et al
    . Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012;122:2807–2816. doi: 10.1172/JCI63563.
    OpenUrlCrossRefPubMed
  139. 139.↵
    1. Sazonova O,
    2. Zhao Y,
    3. Nürnberg S,
    4. Miller C,
    5. Pjanic M,
    6. Castano VG,
    7. Kim JB,
    8. Salfati EL,
    9. Kundaje AB,
    10. Bejerano G,
    11. Assimes T,
    12. Yang X,
    13. Quertermous T.
    Characterization of TCF21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLoS Genet. 2015;11:e1005202. doi: 10.1371/journal.pgen.1005202.
    OpenUrlCrossRefPubMed
  140. 140.↵
    1. Nurnberg ST,
    2. Cheng K,
    3. Raiesdana A,
    4. et al
    . Coronary artery disease associated transcription factor TCF21 regulates smooth muscle precursor cells that contribute to the fibrous cap. PLoS Genet. 2015;11:e1005155. doi: 10.1371/journal.pgen.1005155.
    OpenUrlCrossRefPubMed
  141. 141.↵
    1. Beaudoin M,
    2. Gupta RM,
    3. Won HH,
    4. Lo KS,
    5. Do R,
    6. Henderson CA,
    7. Lavoie-St-Amour C,
    8. Langlois S,
    9. Rivas D,
    10. Lehoux S,
    11. Kathiresan S,
    12. Tardif JC,
    13. Musunuru K,
    14. Lettre G.
    Myocardial infarction-associated SNP at 6p24 interferes with MEF2 binding and associates with PHACTR1 expression levels in human coronary arteries. Arterioscler Thromb Vasc Biol. 2015;35:1472–1479. doi: 10.1161/ATVBAHA.115.305534.
    OpenUrlAbstract/FREE Full Text
  142. 142.↵
    1. Pu X,
    2. Xiao Q,
    3. Kiechl S,
    4. et al
    . ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. Am J Hum Genet. 2013;92:366–374. doi: 10.1016/j.ajhg.2013.01.012.
    OpenUrlCrossRefPubMed
  143. 143.↵
    1. Bauer RC,
    2. Tohyama J,
    3. Cui J,
    4. Cheng L,
    5. Yang J,
    6. Zhang X,
    7. Ou K,
    8. Paschos GK,
    9. Zheng XL,
    10. Parmacek MS,
    11. Rader DJ,
    12. Reilly MP.
    Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation. 2015;131:1202–1213. doi: 10.1161/CIRCULATIONAHA.114.012669.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
February 19, 2016, Volume 118, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Genome-Wide Association Studies
    • Studies in Non-European Populations
    • Mendelian Randomization
    • Utility of a Genetic Risk Score for Risk Assessment and Treatment Decisions
    • Interrogation of Rare Coding Variants Contributing to CAD
    • Beyond the Single SNP
    • Systems Genetics Approach to Understanding the Genetic Basis of CAD
    • From Locus to Function
    • Summary
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Genetics of Coronary Artery Disease
    Ruth McPherson and Anne Tybjaerg-Hansen
    Circulation Research. 2016;118:564-578, originally published February 18, 2016
    https://doi.org/10.1161/CIRCRESAHA.115.306566

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Genetics of Coronary Artery Disease
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Genetics of Coronary Artery Disease
    Ruth McPherson and Anne Tybjaerg-Hansen
    Circulation Research. 2016;118:564-578, originally published February 18, 2016
    https://doi.org/10.1161/CIRCRESAHA.115.306566
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetic, Association Studies
    • Genetics
    • Functional Genomics
  • Vascular Disease
    • Coronary Artery Disease
    • Atherosclerosis

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured